company background image

MJ Holdings OTCPK:MJNE Stock Report

Last Price


Market Cap







07 Aug, 2022


Company Financials
MJNE fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health3/6

MJNE Stock Overview

MJ Holdings, Inc., a cannabis holding company, engages in cultivation management, asset, and infrastructure development business in Nevada.

MJ Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MJ Holdings
Historical stock prices
Current Share PriceUS$0.25
52 Week HighUS$0.48
52 Week LowUS$0.14
1 Month Change-10.55%
3 Month Change9.09%
1 Year Change-29.71%
3 Year Change-48.75%
5 Year Changen/a
Change since IPO-89.35%

Recent News & Updates

Shareholder Returns

MJNEUS PharmaceuticalsUS Market

Return vs Industry: MJNE underperformed the US Pharmaceuticals industry which returned 1.9% over the past year.

Return vs Market: MJNE underperformed the US Market which returned -12.9% over the past year.

Price Volatility

Is MJNE's price volatile compared to industry and market?
MJNE volatility
MJNE Average Weekly Movement13.2%
Pharmaceuticals Industry Average Movement11.8%
Market Average Movement7.9%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: MJNE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: MJNE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

200611Roger Bloss

MJ Holdings, Inc., a cannabis holding company, engages in cultivation management, asset, and infrastructure development business in Nevada. It is also involved in production of cannabis related products; and provision of management services, dispensaries, and consulting services. The company was incorporated in 2006 and is based in Las Vegas, Nevada.

MJ Holdings Fundamentals Summary

How do MJ Holdings's earnings and revenue compare to its market cap?
MJNE fundamental statistics
Market CapUS$19.53m
Earnings (TTM)-US$5.42m
Revenue (TTM)n/a


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MJNE income statement (TTM)
Cost of RevenueUS$341.63k
Gross Profit-US$375.29k
Other ExpensesUS$5.04m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)-0.068
Gross Margin1,114.81%
Net Profit Margin16,089.40%
Debt/Equity Ratio49.7%

How did MJNE perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is MJNE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MJNE?

Other financial metrics that can be useful for relative valuation.

MJNE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue-531.2x
Enterprise Value/EBITDA-2.3x
PEG Ration/a

Price to Book Ratio vs Peers

How does MJNE's PB Ratio compare to its peers?

MJNE PB Ratio vs Peers
The above table shows the PB ratio for MJNE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.2x
TTNP Titan Pharmaceuticals
CING Cingulate
VRPX Virpax Pharmaceuticals
GRAY Graybug Vision
MJNE MJ Holdings

Price-To-Book vs Peers: MJNE is expensive based on its Price-To-Book Ratio (9x) compared to the peer average (1.2x).

Price to Earnings Ratio vs Industry

How does MJNE's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Book vs Industry: MJNE is expensive based on its Price-To-Book Ratio (9x) compared to the US Pharmaceuticals industry average (2x)

Price to Book Ratio vs Fair Ratio

What is MJNE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MJNE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate MJNE's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of MJNE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MJNE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MJNE's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is MJ Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MJ Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Take a look at our analysis of MJNE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access MJ Holdings's filings and announcements here.

Past Performance

How has MJ Holdings performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MJNE is currently unprofitable.

Growing Profit Margin: MJNE is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: MJNE is unprofitable, but has reduced losses over the past 5 years at a rate of 22.6% per year.

Accelerating Growth: Unable to compare MJNE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MJNE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).

Return on Equity

High ROE: MJNE has a negative Return on Equity (-263.88%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is MJ Holdings's financial position?

Financial Health Score


Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MJNE's short term assets ($4.0M) do not cover its short term liabilities ($4.8M).

Long Term Liabilities: MJNE's short term assets ($4.0M) exceed its long term liabilities ($686.3K).

Debt to Equity History and Analysis

Debt Level: MJNE has more cash than its total debt.

Reducing Debt: MJNE's debt to equity ratio has increased from 47.9% to 49.7% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MJNE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MJNE has less than a year of cash runway if free cash flow continues to reduce at historical rates of 4.3% each year

Discover healthy companies


What is MJ Holdings's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MJNE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MJNE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MJNE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MJNE's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MJNE has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Roger Bloss (65 yo)





Mr. Roger J. Bloss serves as the Director at MJ Holdings, Inc. since April 1, 2019 and serves as its Chief Executive Officer since October 26, 2021 and also served as its Interim Chief Executive Officer si...

CEO Compensation Analysis

Compensation vs Market: Roger's total compensation ($USD184.62K) is below average for companies of similar size in the US market ($USD767.73K).

Compensation vs Earnings: Roger's compensation has been consistent with company performance over the past year.

Board Members

Experienced Board: MJNE's board of directors are considered experienced (3.3 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.7%.

Top Shareholders

Company Information

MJ Holdings, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: MJ Holdings, Inc.
  • Ticker: MJNE
  • Exchange: OTCPK
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$19.526m
  • Shares outstanding: 79.37m
  • Website:

Number of Employees


  • MJ Holdings, Inc.
  • 2580 S Sorrel St
  • Las Vegas
  • Nevada
  • 89146
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/07 00:00
End of Day Share Price2022/08/05 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.